NCT04878783Active, not recruiting
Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG
CT Scan-Based Radiomics and Molecular Expression Predictive Model to Assess Tumor Regression Grade Following Perioperative Chemotherapy in Esophago-Gastric Junction and Gastric Cancer
Source: ClinicalTrials.gov · Last updated 9 May 2024
Brief summary (registry, in English)
The aim of this study is to develop a CT scan-based radiomics predictive model about tumor regression grade (TRG) in patients with esophago-gastric junction (EGJ) ang gastric cancer undergoing perioperative chemotherapy. The molecular expression of the neoplasms will be evaluated to assess its association with the TRG and the radiomic features.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 138 (actual)
- First submitted
- 6 May 2021
- Start date
- 20 Dec 2019
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- University of Roma La Sapienza
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT04878783
What you commit to
- Study type: Observational
- Participants enrolled: 138
- From 20 Dec 2019 to the primary completion date, 1 Oct 2024
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients undergoing preoperative radiotherapy.
- Absence of both pre and post-chemotherapy CT-scan.
- Patients with tumor progression during preoperative chemotherapy.
- Patients undergoing other neoadjuvant chemotherapy regimen different from FLOT
Other
- Siewert I EGJ tumor
- Exploratory laparoscopy with positive cytology on the peritoneal lavage or evidence of peritoneal carcinosis
Who the study is looking for
- Patients with histologically proven adenocarcinoma of the EGJ (Siewert II-III) or stomach.
- Preoperative staging: cT2-T4a, cN0-N3, M0.
- Patients \>18 years old.
- Patients undergoing perioperative chemotherapy with Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT).
Age in the registry: 18 years to - · Sex: All
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Padova Coordinator of this site? Confirm its status | Padova | Italy | Unknown status |
| Giovanni Maria Garbarino Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
| Link Campus University Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
| University of Verona Coordinator of this site? Confirm its status | Verona | Italy | Unknown status |
| Amsterdam UMC location University of Amsterdam Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.